share_log

微創醫療：上海微創心脈醫療科技（集團）股份有限公司截至二零二四年三月三十一日止三個月未經審核財務資料

MICROPORT: UNAUDITED FINANCIAL INFORMATION OF SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2024

Hong Kong Stock Exchange ·  Apr 26 09:02
Summary by Moomoo AI
微創醫疗科學有限公司（「微創醫疗」）公布其持股40.32%的上海微創心脈醫療科技（「心脈醫療科技」）截至2024年3月31日止三個月的未經審核財務資料。數據顯示，心脈醫療科技在該季度的收入達到人民幣358,081.4千元，較去年同期的人民幣285,591.4千元增長了25.38%。利潤總額和歸屬於心脈醫療科技股權持有人的淨利潤分別增長了49.56%及47.62%，達到人民幣216,760.7千元和人民幣184,296.1千元。此外，截至2024年3月31日，心脈醫療科技的總資產為人民幣4,524,504.6千元，較2023年12月31日增長了6.55%，而歸屬於心脈醫療科技股權持有人的總權益則增長了5.17%，達到人民幣4,042,715.7千元。微創醫疗提醒股東及潛在投資者，上述財務資料僅反映心脈醫療科技的業務狀況，未經審核，且不全面代表微創醫疗集團的整體業務或狀況。公告由微創醫疗董事會於2024年4月26日發布。
微創醫疗科學有限公司（「微創醫疗」）公布其持股40.32%的上海微創心脈醫療科技（「心脈醫療科技」）截至2024年3月31日止三個月的未經審核財務資料。數據顯示，心脈醫療科技在該季度的收入達到人民幣358,081.4千元，較去年同期的人民幣285,591.4千元增長了25.38%。利潤總額和歸屬於心脈醫療科技股權持有人的淨利潤分別增長了49.56%及47.62%，達到人民幣216,760.7千元和人民幣184,296.1千元。此外，截至2024年3月31日，心脈醫療科技的總資產為人民幣4,524,504.6千元，較2023年12月31日增長了6.55%，而歸屬於心脈醫療科技股權持有人的總權益則增長了5.17%，達到人民幣4,042,715.7千元。微創醫疗提醒股東及潛在投資者，上述財務資料僅反映心脈醫療科技的業務狀況，未經審核，且不全面代表微創醫疗集團的整體業務或狀況。公告由微創醫疗董事會於2024年4月26日發布。
MICROCHUN MEDICAL SCIENCES CO., LTD. (“MICROCHUN MEDICAL”) ANNOUNCES UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED MARCH 31, 2024, OF ITS 40.32% SHAREHOLDING IN SHANGHAI MICROCHUN HEART MEDICAL TECHNOLOGY (“CARDIAC MEDICAL TECHNOLOGY”). Data showed that Cardiac Medical Technology's revenue in the quarter reached RMB358,081.4K, an increase of 25.38% from RMB285,591.4K in the same period last year. Total profit and net profit attributable to Cardiac Medical Technology equity holders increased 49.56% and 47.62% respectively to RMB216,760.7K and RMB184,296.1K. In addition, as of March 31, 2024, Cardiac Medical Technology's total assets were RMB4,524,504.6 thousand, an increase of 6.55% compared to December 31, 2023, and total equity attributable to Cardiac Medical Technology equity holders increased by 5.17% to RMB4,042,715.7 thousand. MICRO HEALTHCARE REMINDS SHAREHOLDERS AND POTENTIAL INVESTORS THAT THE ABOVE FINANCIAL INFORMATION REFLECTS THE BUSINESS STATUS OF CARDIAC HEALTHCARE TECHNOLOGY ONLY, IS UNAUDITED AND DOES NOT FULLY REPRESENT THE OVERALL BUSINESS OR CONDITION OF MICROCHO MEDICAL GROUP. The announcement was issued by the Board of Directors of MicroChung Medical on 26 April 2024.
MICROCHUN MEDICAL SCIENCES CO., LTD. (“MICROCHUN MEDICAL”) ANNOUNCES UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED MARCH 31, 2024, OF ITS 40.32% SHAREHOLDING IN SHANGHAI MICROCHUN HEART MEDICAL TECHNOLOGY (“CARDIAC MEDICAL TECHNOLOGY”). Data showed that Cardiac Medical Technology's revenue in the quarter reached RMB358,081.4K, an increase of 25.38% from RMB285,591.4K in the same period last year. Total profit and net profit attributable to Cardiac Medical Technology equity holders increased 49.56% and 47.62% respectively to RMB216,760.7K and RMB184,296.1K. In addition, as of March 31, 2024, Cardiac Medical Technology's total assets were RMB4,524,504.6 thousand, an increase of 6.55% compared to December 31, 2023, and total equity attributable to Cardiac Medical Technology equity holders increased by 5.17% to RMB4,042,715.7 thousand. MICRO HEALTHCARE REMINDS SHAREHOLDERS AND POTENTIAL INVESTORS THAT THE ABOVE FINANCIAL INFORMATION REFLECTS THE BUSINESS STATUS OF CARDIAC HEALTHCARE TECHNOLOGY ONLY, IS UNAUDITED AND DOES NOT FULLY REPRESENT THE OVERALL BUSINESS OR CONDITION OF MICROCHO MEDICAL GROUP. The announcement was issued by the Board of Directors of MicroChung Medical on 26 April 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more